Join us for the next Lunch & Learn event in collaboration with PharmaLex.

Context: 
The world health demand is great, for small molecule drugs that may one day drug the undruggable and feature superior pharmaceutical characteristics. PharmaLex examines the small molecule innovation opportunity and challenge. During this talk we will discuss the different regulatory pathways available to accelerate development and approval of these innovative drugs. We will also present how Omics analysis can benefit both R&D as well into Regulatory success, when incorporated into therapeutic development programmes.

Speaker Panel: 

Julia Price, Principal Consultant @PharmaLex: Julia has over 30 years of broad-based experience in Regulatory Affairs. For example,  experience in a broad number of therapeutic areas such as biologicals particularly in the area of haemophilia, antibacterials, opthalmics, anti-HIV, oncology, immunology and anti-rheumatics. She will be speaking on pathways to accelerate the development/approval of small molecules.

Tony Gomez, Senior Manager @PharmaLex: Tonywill present on how Omics analysis can benefit both R&D as well into Regulatory success, when incorporated into therapeutic development programs. He has more than 12 years working as a Bioinformatician analyzing Next Generation Sequencing Genomic Data from several human diseases (Cancer, Immune Mediated Inflammatory Diseases (IMIDs) , Cardiac and Rare diseases, Diabetes,...). High skills in different bioinformatics approaches to cope with methylation, expression, genetic variants, chromatin states…

This event is free to attend and open to all.